JMP Securities initiated coverage on Lantheus Holdings with a new price target
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
JMP Securities initiated coverage of Lantheus Holdings with a rating of Mkt Outperform and set a new price target of $120.00